521 related articles for article (PubMed ID: 15197808)
1. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study.
Mocroft A; Kirk O; Clumeck N; Gargalianos-Kakolyris P; Trocha H; Chentsova N; Antunes F; Stellbrink HJ; Phillips AN; Lundgren JD
Cancer; 2004 Jun; 100(12):2644-54. PubMed ID: 15197808
[TBL] [Abstract][Full Text] [Related]
2. Kaposi's sarcoma in patients with human immunodeficiency virus infection in Taiwan.
Lin CY; Chen MY; Hsieh SM; Sheng WH; Sun HY; Lo YC; Hung CC; Chang SC
J Microbiol Immunol Infect; 2009 Jun; 42(3):227-33. PubMed ID: 19812856
[TBL] [Abstract][Full Text] [Related]
3. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
Clifford GM; Polesel J; Rickenbach M; Dal Maso L; Keiser O; Kofler A; Rapiti E; Levi F; Jundt G; Fisch T; Bordoni A; De Weck D; Franceschi S;
J Natl Cancer Inst; 2005 Mar; 97(6):425-32. PubMed ID: 15770006
[TBL] [Abstract][Full Text] [Related]
4. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group.
Mocroft A; Ledergerber B; Viard JP; Staszewski S; Murphy M; Chiesi A; Horban A; Hansen AB; Phillips AN; Lundgren JD;
J Infect Dis; 2004 Dec; 190(11):1947-56. PubMed ID: 15529259
[TBL] [Abstract][Full Text] [Related]
5. Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy.
Gallafent JH; Buskin SE; De Turk PB; Aboulafia DM
J Clin Oncol; 2005 Feb; 23(6):1253-60. PubMed ID: 15718323
[TBL] [Abstract][Full Text] [Related]
6. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
Ives NJ; Gazzard BG; Easterbrook PJ
J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
[TBL] [Abstract][Full Text] [Related]
7. Decline in esophageal candidiasis and use of antimycotics in European patients with HIV.
Mocroft A; Oancea C; van Lunzen J; Vanhems P; Banhegyi D; Chiesi A; Vinogradova E; Maayan S; Phillips AN; Lundgren J;
Am J Gastroenterol; 2005 Jul; 100(7):1446-54. PubMed ID: 15984964
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of AIDS-related Kaposi's sarcoma in Europe over 10 years. AIDS in Europe Study Group.
Hermans P; Lundgren J; Sommereijns B; Pedersen C; Vella S; Katlama C; Lüthy R; Pinching AJ; Gerstoft J; Pehrson P; Clumeck N
AIDS; 1996 Jul; 10(8):911-7. PubMed ID: 8828749
[TBL] [Abstract][Full Text] [Related]
9. Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma.
Nasti G; Martellotta F; Berretta M; Mena M; Fasan M; Di Perri G; Talamini R; Pagano G; Montroni M; Cinelli R; Vaccher E; D'Arminio Monforte A; Tirelli U; ;
Cancer; 2003 Dec; 98(11):2440-6. PubMed ID: 14635079
[TBL] [Abstract][Full Text] [Related]
10. AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals.
Nasti G; Talamini R; Antinori A; Martellotta F; Jacchetti G; Chiodo F; Ballardini G; Stoppini L; Di Perri G; Mena M; Tavio M; Vaccher E; D'Arminio Monforte A; Tirelli U;
J Clin Oncol; 2003 Aug; 21(15):2876-82. PubMed ID: 12885804
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group.
Gallant JE; Moore RD; Richman DD; Keruly J; Chaisson RE
Arch Intern Med; 1994 Mar; 154(5):566-72. PubMed ID: 8122950
[TBL] [Abstract][Full Text] [Related]
12. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
Ortega KL; Vale DA; Magalhães MH
J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
[TBL] [Abstract][Full Text] [Related]
13. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study.
Dragsted UB; Mocroft A; Vella S; Viard JP; Hansen AB; Panos G; Mercey D; Machala L; Horban A; Lundgren JD;
J Infect Dis; 2004 Jul; 190(1):148-55. PubMed ID: 15195254
[TBL] [Abstract][Full Text] [Related]
14. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
Martín-Carbonero L; Palacios R; Valencia E; Saballs P; Sirera G; Santos I; Baldobí F; Alegre M; Goyenechea A; Pedreira J; González del Castillo J; Martínez-Lacasa J; Ocampo A; Alsina M; Santos J; Podzamczer D; González-Lahoz J;
Clin Infect Dis; 2008 Aug; 47(3):410-7. PubMed ID: 18582203
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda.
Asiimwe F; Moore D; Were W; Nakityo R; Campbell J; Barasa A; Mermin J; Kaharuza F
HIV Med; 2012 Mar; 13(3):166-71. PubMed ID: 22112164
[TBL] [Abstract][Full Text] [Related]
16. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women.
Ahdieh-Grant L; Li R; Levine AM; Massad LS; Strickler HD; Minkoff H; Moxley M; Palefsky J; Sacks H; Burk RD; Gange SJ
J Natl Cancer Inst; 2004 Jul; 96(14):1070-6. PubMed ID: 15265968
[TBL] [Abstract][Full Text] [Related]
17. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
18. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy.
d'Arminio Monforte A; Sabin CA; Phillips A; Sterne J; May M; Justice A; Dabis F; Grabar S; Ledergerber B; Gill J; Reiss P; Egger M;
Arch Intern Med; 2005 Feb; 165(4):416-23. PubMed ID: 15738371
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France.
Bonnet F; Balestre E; Thiébaut R; Morlat P; Pellegrin JL; Neau D; Dabis F;
Clin Infect Dis; 2006 Feb; 42(3):411-7. PubMed ID: 16392091
[TBL] [Abstract][Full Text] [Related]
20. The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta.
Gingues S; Gill MJ
HIV Med; 2006 Sep; 7(6):369-77. PubMed ID: 16903981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]